August 31, 2017 07:21 AM EDT
R&D

In­cyte's good week con­tin­ues with an en­cour­ag­ing up­date on IDO1 star epaca­do­stat

John Carroll

Editor & Founder

In­cyte’s com­plete re­sponse rate for a mid-stage com­bo of its IDO1 drug epaca­do­stat with check­point leg­end Keytru­da took a hit in the lat­est da­ta up­date …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times